



## **NEW IMPROVED DOSING APPROVED FOR PENNSAID**

**Mississauga, Ontario, Canada – June 3, 2008 - Nuvo Research Inc. (TSX: NRI)**, a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, and **Paladin Labs Inc. (TSX: PLB)**, a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved a new dosing regimen for Pennsaid® (topical diclofenac). Paladin sells and markets Pennsaid in Canada, having acquired exclusive Canadian Pennsaid rights from Nuvo in August 2005.

The new dosing regimen of Pennsaid® will be 50 drops per knee, 3 times a day, as an alternative to the existing approved dosing regimen of 40 drops per knee, 4 times a day. Pennsaid had Canadian sales of \$10.6 million last year and has been sold in Canada since May 2003.

“Pennsaid® is a proven effective treatment for Osteoarthritis of the knee,” said Dr. Philip Baer, a Rheumatologist practicing in Ontario. “The newly approved dosing regimen of 50 drops TID (three-time-per-day) will make it easier for patients to use Pennsaid® to manage their pain, as compared to applying 40 drops QID (four-times-per-day). TID dosing can improve patient compliance, which is one of the most important factors in ensuring effective pain relief.”

“The new improved dosing regimen of Pennsaid® is a significant clinical advantage,” said Henrich Guntermann, Nuvo’s President and CEO. “We are eager to replicate Pennsaid’s Canadian success in the U.S. market and continue to work diligently on obtaining U.S. FDA approval.”

### **About Paladin Labs Inc.**

Paladin Labs Inc., headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada’s leading specialty pharmaceutical companies. Paladin’s shares trade on the Toronto Stock Exchange under the symbol *PLB*. For more information about Paladin, please visit the Paladin web site at [www.paladinlabs.com](http://www.paladinlabs.com).

### **About Nuvo Research Inc.**

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo’s lead product is Pennsaid®, a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Québec and Wanzleben, Germany and a research and development Center in San Diego California. For more information, please visit [www.nuvoresearch.com](http://www.nuvoresearch.com).

*These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ*

*materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2007. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at [www.sedar.com](http://www.sedar.com).*

**For more information about Paladin, please contact:**

Samira Sakhia

Chief Financial Officer

**Paladin Labs Inc.**

Tel: (514) 340-5067

email: [info@paladin-labs.com](mailto:info@paladin-labs.com)

**For more information about Nuvo, please contact:**

Investor Relations

Christina Bessant

**Equicom Group Inc.**

Tel: (416) 815-0700 x269

email: [cbessant@equicomgroup.com](mailto:cbessant@equicomgroup.com)